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Type 2 diabetes (T2D) has become epidemic in our
modern lifestyle, likely due to calorie-rich diets over-
whelming our adaptive metabolic pathways. One
such pathway is mediated by nicotinamide phos-
phoribosyltransferase (NAMPT), the rate-limiting
enzyme in mammalian NAD+ biosynthesis, and the
NAD+-dependent protein deacetylase SIRT1. Here,
we show that NAMPT-mediated NAD+ biosynthesis
is severely compromised in metabolic organs by
high-fat diet (HFD). Strikingly, nicotinamide mononu-
cleotide (NMN), a product of the NAMPT reaction
and a key NAD+ intermediate, ameliorates glucose
intolerance by restoring NAD+ levels in HFD-induced
T2D mice. NMN also enhances hepatic insulin sensi-
tivity and restores gene expression related to oxida-
tive stress, inflammatory response, and circadian
rhythm, partly through SIRT1 activation. Further-
more, NAD+ and NAMPT levels show significant
decreases in multiple organs during aging, and
NMN improves glucose intolerance and lipid profiles
in age-inducedT2Dmice. These findingsprovide crit-
ical insights into a potential nutriceutical intervention
against diet- and age-induced T2D.
INTRODUCTION
Recent studies have raised an interesting possibility that various
physiological mechanisms that mediate metabolic adaptation
have evolved in response to nutritionally scarce conditions
such as famine and drought (Lazar, 2005). In our modern, seden-
tary lifestyle with calorie-rich diets, such adaptive mechanisms
could be seriously overwhelmed, causing an epidemic of obesity
and T2D worldwide (Yach et al., 2006). In mammals, one such
mechanism comprises NAMPT-mediated NAD+ biosynthesis
and the NAD+-dependent protein deacetylase SIRT1 (Haigis and
Sinclair, 2010; Imai, 2010; Imai and Guarente, 2010). NAMPT-
mediated NAD+ biosynthesis and SIRT1 together play critical
roles in regulating a variety of biological processes that include
metabolism, stress response, cellular differentiation, and circa-
dian rhythm, as well as mediating adaptive responses to limited
energy intake, such as fasting and diet restriction (Imai, 2010).528 Cell Metabolism 14, 528–536, October 5, 2011 ª2011 Elsevier InFor example, in skeletal muscle, both nutritional deprivation
and exercise increase Nampt expression through the activation
of AMP-activated protein kinase (AMPK), thereby enhancing
NAD+ biosynthesis and SIRT1 activity (Canto´ et al., 2010; Fulco
et al., 2008). In pancreatic b cells, both NAMPT-mediated NAD+
biosynthesis and SIRT1 regulate glucose-stimulated insulin
secretion (GSIS) in response to glucose availability (Moynihan
et al., 2005; Revollo et al., 2007). Additionally, in the liver and in
white adipose tissue (WAT), NAMPT and SIRT1 comprise a tran-
scriptional-enzymatic feedback loop for the regulation of circa-
dian rhythm, a powerful effector for metabolism (Imai, 2010).
How nutritional and environmental perturbations affect the
system dynamics of this NAMPT/NAD+/SIRT1-driven adaptive,
systemic regulatory network named the ‘‘NAD World’’ (Imai,
2010) still remains unclear. Here, we show that high-fat diet
(HFD) and aging compromise NAMPT-mediated NAD+ biosyn-
thesis, contributing to the pathogenesis of T2D. Importantly,
we also provide evidence that promoting NAD+ biosynthesis
by using nicotinamide mononucleotide (NMN), a product of the
NAMPT reaction and a key NAD+ intermediate, could be an
effective intervention against diet- and age-induced T2D.
RESULTS
NAMPT-Mediated NAD+ Biosynthesis Is Compromised
by HFD
To examine the connection between NAMPT-mediated NAD+
biosynthesis and T2D, wild-type B6 male and female mice at
3–6 months of age were fed a HFD containing 42% calories
from fat. Both males and females developed overt diabetes after
3.5 and 6 months, respectively. In these mice, we found that
NAMPT protein levels were significantly reduced in the liver
and WAT, but not in skeletal muscle, compared to regular
chow (RC)-fed control mice (Figure 1A and Figures S1A and
S1B available online). Consistent with these decreases in
NAMPT levels, NAD+ levels were also significantly reduced in
the liver and WAT, but not in skeletal muscle (Figures 1B and
S1C), indicating that there is an underlying defect in NAD+
biosynthesis in the liver and WAT of HFD-induced diabetic mice.
NMN Ameliorates Defects in NAD+ Biosynthesis
and Glucose Metabolism in T2D Mice
Based on these findings, we hypothesized that the defect in
NAMPT-mediated NAD+ biosynthesis could be ameliorated by
administering NMN to diabetic mice. To test this idea, we initiallyc.
Figure 1. NMN Ameliorates Defects in NAMPT-Mediated NAD+ Biosynthesis in HFD-Induced Diabetic Mice
(A) NAMPT protein levels in the liver, WAT, and skeletal muscle. Female mice were fed a RC or a HFD for 6–8 months. NAMPT levels were normalized to ACTIN
(liver) or TUBULIN (WAT and skeletal muscle) (n = 4–5 mice per group).
(B) Tissue NAD+ levels in the liver, WAT, and skeletal muscle from RC-, HFD-, and NMN-treated HFD mice (n = 5–13 mice per group). NMN (500 mg/kg body
weight/day) was given intraperitoneally to HFD-fed female mice for 7 consecutive days.
(C) Changes in NMN and NAD+ levels in the liver after administering a single dose of NMN to B6 mice (n = 3–5 mice for each time point).
(D and E) Intracellular NAD+ levels in mouse primary hepatocytes. Cells were treated with NMN at the indicated concentrations (D) or with enzyme inhibitors
(500 nM FK866 or 100 mM gallotannin [GTN]) in the presence or absence of 100 mM NMN (E) for 4 hr (n = 3 per group).
Data were analyzed by the Student’s unpaired t test (A) and one-way ANOVAwith the Fisher’s PLSD posthoc test (B, D, and E). All values are presented asmean ±
SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2. NMN Administration Improves Impaired Glucose Tolerance in HFD-Induced Diabetic Mice
(A and D)Glucose tolerance in HFD female (n = 10) (A) andmale (n = 6)mice (D) before and after NMN treatment. IPGTTswere conducted with the same individuals
before (closed circles) and after (open circles) NMN. NMN (500mg/kg bodyweight/day) was administered to female andmalemice for 7 and 10 consecutive days,
respectively. The areas under each glucose tolerance curve are presented next to the glucose tolerance curves.
(B and E) Plasma insulin levels in female (n = 10) (B) and male (n = 6) (E) mice during IPGTTs before and after NMN treatment.
(C and F) Insulin tolerance in HFD female (n = 10) (C) and male (n = 6) (F) mice before and after NMN treatment. ITTs were performed before (closed circles) and
after (open circles) NMN. ITTs were conducted several days before or after IPGTTs. The areas under each insulin tolerance curve are presented next to the insulin
tolerance curves.
Data were analyzed by the Student’s paired t test. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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in the liver, pancreas, and WAT. NMN was immediately utilized
and converted to NAD+ within 15 min, resulting in significant
increases in NAD+ levels over 60 min (Figures 1C and S1D). We
also observed a mild increase (5-fold) in nicotinamide riboside
(NR) levels compared to an 15-fold increase of NMN, implying
that a part of NMN might be converted to NR to get into the liver
(Figure S1E). We further confirmed that NMN enhanced NAD+
biosynthesis in mouse primary hepatocytes in a dose-dependent
manner (Figure 1D). NMN was also able to overcome NAD+ defi-
cits caused by a potent NAMPT inhibitor FK866 (Hasmann and
Schemainda, 2003), but it was unable to alleviate the NAD+
reduction, due to the inhibition of nicotinamide/nicotinic acid
mononucleotide adenylyltransferases (NMNATs) by their potent
inhibitor, gallotannin (Berger et al., 2005) (Figures 1E and S1F).530 Cell Metabolism 14, 528–536, October 5, 2011 ª2011 Elsevier InThese results demonstrate the effectiveness and specificity of
NMN at stimulating NAD+ biosynthesis in vivo and in vitro.
Given these findings, we administered NMN at a dose of
500 mg/kg body weight/day intraperitoneally to HFD-fed male
and female diabetic mice for 10 and 7 consecutive days, respec-
tively. No overt abnormalities or changes in body weight were
detected during this time (data not shown). NMN administration
successfully restored NAD+ levels in the liver and WAT of dia-
betic mice, and even in diabetic skeletal muscle, a moderate
but significant increase in NAD+ was detected (Figure 1B). These
results demonstrate the efficacy of NMN treatment in amelio-
rating the underlying defect in NAD+ biosynthesis in HFD-
induced diabetes.
Strikingly, NMN administration completely normalized im-
paired glucose tolerance in diabetic female mice (Figure 2A).c.
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tolerance tests (IPGTTs) did not differ before and after NMN
treatment, insulin tolerance was significantly improved in these
females (Figures 2B and 2C). In diabeticmales, NMNdid improve
impaired glucose tolerance, but the effect was milder compared
to the females (Figure 2D). Different from females, GSIS in males
was enhanced at 15 and 30min time points in IPGTTs after NMN
administration (Figure 2E). Using primary pancreatic islets iso-
lated from diabetic males, we also confirmed that both NAD+
levels and GSIS were enhanced by NMN (Figure S2). On the
other hand, insulin tolerance remained unchanged in males
(Figures 2F), suggesting that NMN exerts its major effects on
different target tissues between males and females. Although
the reason for this sex difference is currently unclear, these
results demonstrate that NMN treatment can ameliorate
impaired glucose tolerance by improving either insulin sensitivity
or insulin secretion in HFD-induced diabetic mice.
NMN Enhances Hepatic Insulin Sensitivity by Reversing
Gene Expression Caused by HFD
Given that NMN administration restored normal NAD+ levels in
diabetic livers (Figure 1B) and also that the liver is known to
have a major effect on insulin sensitivity in mice, we examined
whether NMN improves hepatic insulin sensitivity in diabetic
females. We first assessed the phosphorylation status of AKT,
a downstream kinase in insulin signaling, in diabetic livers with
or without NMN treatment. Clear increases in AKT phosphoryla-
tion were detected in NMN-treated diabetic mice, indicating that
hepatic insulin sensitivity is improved by NMN treatment (Fig-
ure 3A). We then compared gene expression profiles between
RC-fed, HFD-fed, and NMN-treated HFD-fed livers. We also
performed PAGE (Kim and Volsky, 2005) using these gene
expression data and GO gene sets. Interestingly, the biological
pathways and genes related to oxidative stress, inflammatory
response, immune response, and lipid metabolism, all of which
are known to contribute to hepatic insulin resistance (Mattson,
2009; Shoelson et al., 2006), were affected by HFD and reversed
by NMN (Figures 3B and S3A). For example, pathways related to
glutathione S-transferases, which play an important role in
protection from lipid peroxidation products and, thereby, the
maintenance of hepatic insulin sensitivity (Mattson, 2009), were
suppressed by HFD and restored by NMN (Figure 3B, GO:
0004364 and GO: 0016765). Indeed, expression levels of the
glutathione S-transferase alpha 2 gene (Gsta2) were significantly
reduced by HFD and recovered by NMN (Figures 3C). Gsta1
and Gsta4 also showed the same directions of changes
(12.3 and 6.18 for the sum of Z ratio, respectively), although
their false discovery rates did not reach statistical significance
(data not shown). Pathways related to damage, inflammatory,
and immune responses were induced by HFD and suppressed
by NMN (Figure 3B, GO:0006952, GO:0006954, GO:0009611,
GO:0006955, and GO:0009605). Consistent with these pathway
alterations, expression levels of the interleukin 1b gene (Il1b) and
the S100 calcium-binding protein A8 and A9 genes (S100a8 and
S100a9), which are all direct nuclear factor-kappa B (NF-kB)
target genes and play important roles in hepatic insulin resis-
tance (Ne´meth et al., 2009; Nov et al., 2010), were significantly
upregulated by HFD and downregulated by NMN (Figures 3C
and S3A). Other genes that showed significant changes byCellboth HFD and NMN, such as Lipin1 (Croce et al., 2007) and pyru-
vate dehydrogenase kinase 4 (Pdk4) (Jeoung and Harris, 2008),
have also been connected to insulin resistance. It should also
be noted that expression of genes related to circadian rhythm
(such as Dbp, Dec1, and Rev-erb-a) were altered by HFD and
reversed by NMN (Figures 3C). The genes regulated by DBP,
such as Cyp2a5 and Rgs16, also showed similar expression
profiles (Figure 3C and S3A). These findings provide strong
support for the importance of NAMPT-mediated NAD+ biosyn-
thesis in the connection between circadian rhythm and meta-
bolic disorders (Imai, 2010).
SIRT1 Is One of the Mediators for the Effect of NMN
To elucidate which transcription factors mediate expression
changes by HFD and NMN, biological network analysis was per-
formed using the shortest path and the transcription regulation
(TR) algorithms (Figure S3B). We noticed that transcription
factors that formed relatively large hubs in the deduced network,
such as c-Myc, NF-kB, PPARg, and p53, are all reported targets
of SIRT1 (Figure S3C), implying that SIRT1 might be one of the
mediators for the observed gene expression changes. Given
that NF-kB is regulated by SIRT1-mediated deacetylation
(Yeung et al., 2004) and plays a critical role in hepatic insulin
resistance (Shoelson et al., 2006), we analyzed the acetylation
status of NF-kB in livers from each experimental condition
(Figure 3D). Consistent with the changes in NAD+ levels and
NF-kB target gene expression, levels of acetylated p65, a
component of NF-kB, increased by HFD and decreased consid-
erably by NMN, suggesting that SIRT1 activity is suppressed by
HFD and restored by NMN.
Because both inflammatory cytokines and oxidative stress are
linked to hepatic insulin resistance (Evans et al., 2005; Peraldi
and Spiegelman, 1998), we also tested whether tumor necrosis
factor-alpha (TNF-a) and menadione can affect NAMPT-medi-
ated NAD+ biosynthesis and cause similar gene expression
changes in vitro. Interestingly, whereas both reagents were
able to significantly reduce NAMPT and NAD+ levels in primary
hepatocytes, only TNF-a showed gene expression patterns
similar to those in HFD-fed diabetic livers (Figures 3E, 3F, and
S3D and data not shown). This TNF-a-mediated decrease in
NAD+ levels was ameliorated by NMN (Figure 3F). In TNF-a/
NMN-treated primary hepatocytes, NMN was able to restore
the Gsta2 expression to a similar level observed in HFD-fed,
NMN-treated livers, and its effect was abrogated by EX527,
a potent SIRT1-specific inhibitor, further confirming that SIRT1
is at least one of the mediators for the effect of NMN (Figure 3G).
NMN Ameliorates Metabolic Complications
in Age-Induced T2D Mice
In addition to calorie-rich diets, aging is one of the greatest risk
factors for developing T2D (Møller et al., 2003). We found that
NAD+ levels showed significant decreases in the pancreas,
WAT, and skeletal muscle and also the same trend with a
much larger variation in the liver in old mice, compared to those
in young mice (Figure 4A). NAMPT protein levels also decreased
in those tissues (Figures S4A and S4B). Based on these findings,
we speculated that NMN treatment might also be effective in
age-induced T2D models. We screened RC wild-type B6 males
and females at 15–26 months of age and found 15% of malesMetabolism 14, 528–536, October 5, 2011 ª2011 Elsevier Inc. 531
Cell Metabolism
Therapeutic Potential of NMN for Type 2 Diabetes
532 Cell Metabolism 14, 528–536, October 5, 2011 ª2011 Elsevier Inc.
Cell Metabolism
Therapeutic Potential of NMN for Type 2 Diabetesdiabetic (>200mg/dl at 2 hr time point in IPGTTs). To these aged,
naturally occurring diabetic male mice, we intraperitoneally
administered the same dose of NMN. Surprisingly, just one
dose of NMN normalized impaired glucose tolerance (Figure 4B).
In these mice, GSIS at 15 and 30 min time points during
IPGTTs were higher after NMN treatment, although the differ-
ence did not reach statistical significance (Figure 4C). This is
consistent with the results in HFD-induced diabetic male mice
(Figure 2E). Importantly, NMN did not convey any significant
effects to aged nondiabetic male mice (Figures S4C and S4D),
indicating that NMN treatment is effective for age-induced dia-
betic individuals and does not negatively affect glucose homeo-
stasis in nondiabetic individuals. Because females proved diffi-
cult to naturally develop T2D, we fed aged female mice a HFD
for 7 weeks. Unlike younger females, aged females were very
susceptible to HFD and developed severe diabetes within this
time frame. In theseaged, diabetic females, 11consecutive injec-
tions of NMN completely normalized severely impaired glucose
tolerance (Figure 4D). Qualitatively consistent with this improve-
ment, their respiratory quotient showed a significant increase
after NMN treatment, thereby implicating better glucose utiliza-
tion, although their oxygen consumption did not change (Fig-
ure S4E). Rectal body temperature also decreased, which might
be explained by a significant shift in energy utilization from fat
to glucose (Figure S4F). Furthermore, hyperlipidemia induced
by HFD was also corrected by NMN (Figure 4E). Thus, these
results support the efficacy of NMN to significantly improve
impaired glucose tolerance in age-induced T2D, as well as in
HFD-induced T2D.
DISCUSSION
The results presented in this study demonstrate that NAMPT-
mediated NAD+ biosynthesis is compromised by HFD and
aging, contributing to the pathogenesis of T2D. We also provide
proof of the concept that promoting NAD+ biosynthesis by
administering NMN, a key NAD+ intermediate, can be an effec-
tive intervention to treat the pathophysiology of diet- and age-
induced T2D (Figure S4G). In both diabetic models, NMN admin-
istration dramatically ameliorated impaired glucose toleranceFigure 3. NMNAmeliorates Hepatic Insulin Resistance and Restores G
and Circadian Rhythm
(A) The phosphorylation status of AKT in HFD and NMN-treated HFD female livers
total AKT protein levels.
(B) Biological pathways that were altered by HFD and reversed by NMN in fem
upregulated (red) or downregulated (blue) by either HFD or NMN, using our mic
following the sum of the absolute values of Z scores between two comparisons.
(C) Quantitative RT-PCR results for representative genes related to oxidative stres
group). Gsta2, glutathione S-transferase alpha 2; Il1b, interleukin 1 beta; Pdk4,
(albumin D box) binding protein; Dec1, deleted in esophageal cancer 1.
(D) Acetylation status of NF-kB p65 in RC-, HFD-, and NMN-treated HFD livers. T
each panel represent normalized ratios of acetylated to total p65 levels.
(E–G) The effects of TNF-a on NAMPT-mediated NAD+ biosynthesis and gene
TNF-a for 72 hr and given indicated reagents for 6 hr prior to harvesting for mea
(E) NAMPT protein levels were normalized to ACTIN (n = 3 per group).
(F) TNF-a-treated cells were given 100 mM NMN prior to NAD+ measurements (n
(G) TNF-a-treated cells were cultured with NMN or NMN plus 40 mM EX527 and
Data were analyzed by the Student’s unpaired t test (A and E). Differences in Ct va
post-hoc test (C, F, and G). All values are presented as mean ± SEM. *p < 0.05;
Cellby restoring normal NAD+ levels and enhancing either insulin
sensitivity or insulin secretion, supporting our conclusion that
underlying defects in NAMPT-mediated NAD+ biosynthesis
play an important role in the pathogenesis of diet- and age-
induced T2D. Although the short-term NMN administration was
unable to achieve a significant improvement of fasted glucose
levels, NMN is still effective at normalizing multiple metabolic
pathways (e.g., oxidative stress, inflammatory response, and
circadian rhythm) and GSIS in T2D. Although the mechanism
for transporting NMN into cells currently remains unknown,
metabolic tissues and organs seem to utilize NMN and convert
it to NAD+ efficiently. Therefore, an adequate and consistent
supply of this key NAD+ intermediate must be critical to maintain
normal hepatic insulin sensitivity and GSIS in pancreatic b cells.
To assess beneficial and possible adverse effects of NMN more
comprehensively, we are currently conducting long-term NMN
supplementation experiments in different dietary conditions.
Inflammation and/or oxidative stress caused by hepatosteato-
sis or aging appear to trigger the reduction in NAMPT-mediated
NAD+ biosynthesis and contribute to the pathogenesis of T2D.
Given that NMN is capable of reversing changes in gene expres-
sion related to oxidative stress, inflammatory response, and
circadian rhythm, NAMPT-mediated NAD+ biosynthesis regu-
lates homeostatic, protective mechanisms against nutritional
perturbations, such as HFD. Our results also indicate that
SIRT1 is at least one of the mediators for these beneficial effects
of NMN on hepatic insulin sensitivity. In addition to SIRT1, there
might be other NAD+-sensitive or NAD+-consuming factors that
also contribute to the effects of NMN. For example, other sirtuin
family members (e.g., SIRT2–7) also likely play some roles in the
metabolic effects of NMN. Particularly, the functions of mito-
chondrial sirtuins (e.g., SIRT3–5) might be affected by deficits
in NAMPT-mediated NAD+ biosynthesis, potentially resulting in
the mitochondrial dysfunction observed in T2D (Lowell and
Shulman, 2005). The sex difference that we observed in this
study is also interesting. Given that estrogen signaling is critical
for the regulation of hepatic insulin sensitivity and GSIS (Meyer
et al., 2011), estrogen might play a role in the effects of NMN
under HFD. Further investigation will be required to identify
detailed mechanisms for the efficacy of NMN.ene Expression Related to Oxidative Stress, Inflammatory Response,
(n = 3mice per group). Signal levels of phosphorylated AKT were normalized to
ale livers. PAGE was performed to identify pathways that were significantly
roarray data (n = 4 mice for each condition). Twenty top pathways are listed
s, inflammatory response, circadian rhythm, and metabolism (n = 4–5 mice per
pyruvate dehydrogenase kinase isozyme 4; Dbp, D site of albumin promoter
wo independent sets of mice were used for this analysis. The numbers below
expression in mouse primary hepatocytes. Cells were treated with 50 ng/ml
surements.
= 3–6 per group).
examined for Gsta2 expression (n = 6–9 per group).
lues or NAD+ levels were analyzed with one-way ANOVAwith the Fisher’s PLSD
**p < 0.01; ***p < 0.001.
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Figure 4. NMN Improves Glucose and Lipid Homeostasis in Age-Induced T2D
(A) NAD+ levels in metabolic tissues between young and old mice. Pancreas, liver, WAT, and skeletal muscle were collected from young (n = 5–11) and old
(n = 5–15) mice at 3–6 and 25–31 months of age, respectively.
(B) Glucose tolerance in aged, naturally occurring diabeticmalemice before (closed circles) and after (open circles) a single dose of NMN (500mg/kg bodyweight)
(n = 11). The areas under each glucose tolerance curve are presented next to the glucose tolerance curves.
(C) Plasma insulin levels were measured during IPGTTs (n = 5).
(D and E) Glucose tolerance (D) and lipid levels (E) in aged HFD female mice before (closed circles) and after (open circles) NMN (n = 5). Fasted plasma samples
were collected from the same mice and subjected to the measurements of cholesterol (Chol), triglycerides (TG), and nonesterified free fatty acids (FFA).
Data were analyzed by the Student’s unpaired t test (A), paired t test (B–D), and one-way ANOVAwith the Fisher’s PLSD posthoc test (E). All values are presented
as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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supplementation might also be effective in human T2D patients
with defects in NAMPT-mediated NAD+ biosynthesis. Because
NMN is an endogenous compound, this is rather a nutriceutical
approach to T2D. Nonetheless, it will be of great interest to
examine whether the effects of NMN are synergistic with those534 Cell Metabolism 14, 528–536, October 5, 2011 ª2011 Elsevier Inof small chemical SIRT1 activators (Haigis and Sinclair, 2010),
particularly in aged, diabetic individuals. Taken together, we
anticipate that long-term NMN administration might be a highly
effective way to sustain enhanced SIRT1 activity in tissues and
organs with compromised NAMPT-mediated NAD+ biosynthesis
and also to combat against the disconcerting epidemic of T2D.c.
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Animal Experimentation
For the HFD-induced T2D model, mice at 3–6 months of age were fed a HFD
containing 42% of the total calories from fat (TD88137; Harlan Taklad). We
defined diabetes as mice having fasted blood glucose levels > 120 mg/dl
or blood glucose levels at 2 hr time point in IPGTTs R 200 mg/dl. To obtain
age-induced diabetic mice, we screened male and female mice at 15–
26 months of age following the criteria. For NMN treatment, we intraperitone-
ally administered NMN (Sigma) at the dose of 500 mg/kg body weight/day, as
indicated in the text and figure legends. This dose was determined in our
previous studies (Ramsey et al., 2008). All animal studies were approved by
the Washington University Animal Studies Committee. Details are available
in the Supplemental Experimental Procedures.
NAD+ and NMN Measurements
NAD+ and NMN levels were determined using an HPLC system (Shimadzu)
with a Supelco LC-18-T column (15cm x 4.6cm; Sigma) and a Hypercarb
column (15cm 3 4.6cm; Thermo Scientific), respectively. Details are available
in the Supplemental Experimental Procedures.
Primary Hepatocyte Isolation
Primary hepatocytes were isolated and cultured as described previously
(Grimm et al., 2011). For treatments with NMN, enzyme inhibitors (FK866,
gallotannin, EX527), TNF-a, and menadione, hepatocytes were cultured in
DMEM containing 1.0% FBS and each reagent or their combinations, as indi-
cated in the text.
Micoroarrays
Total RNA was isolated from frozen liver samples of RC-, HFD-, and NMN-
treated HFD mice and used for Illumina Mouse Ref 8 whole genome microar-
rays (version 2). Details are available in the Supplemental Experimental
Procedures.
Quantitative Real-Time PCR
Real-time PCR was performed using the 7900HT Fast Real-Time PCR System
(Applied Biosystems). Relative expression levels were determined based on
the CT values and normalized to CT values for the Gapdh gene. p values for
the differences of CT values were calculated using one-way ANOVA with the
Fisher’s PLSD test.
Detection of Acetylated NF-kB p65
Nuclear extracts were prepared from frozen liver samples, as previously
described (Rodgers and Puigserver, 2007). Liver nuclear extract (100 mg)
was analyzed by western blotting with an anti-acetyl NF-kB p65 (Lys310) anti-
body (Cell Signaling Technology). The same blot was reprobed with anti-NF-
kB p65 antibody (Santa Cruz). Signals were visualized using the ECL Plus
detection system (Amersham).
Statistical Analyses
Differences between two groups were assessed using the Student’s paired or
unpaired t test. Comparisons among several groups were performed using
one-way ANOVA with the Fisher’s PLSD posthoc test. p values < 0.05 were
considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information include Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/
j.cmet.2011.08.014.
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